Fibrocell Science Technology Leads to Discovery of Two Rare Adult Stem Cell-Like Subpopulations in Human Skin

EXTON, Pa.--(BUSINESS WIRE)--

In collaboration with Fibrocell Science, Inc., (OTCBB:FCSC.OB), researchers at the University of California, Los Angeles (UCLA) have identified two rare adult stem cell-like subpopulations in adult human skin, a discovery that may yield further ground-breaking research in the field of personalized medicine for a broad range of diseases. Using technology developed by Fibrocell Science, Inc. the researchers were able to confirm the existence of these two types of cells in human skin cell cultures, potentially providing a source of stem cell-like subpopulations from skin biopsies, which are quicker to perform, relatively painless and less invasive than bone marrow and adipose tissue extractions, which are the current methods for deriving adult stem cells for patient-specific cellular therapies.

The findings, which are reported in the inaugural issue of BioResearch Open Access, pertain to two subtypes of cells: SSEA3-expressing regeneration-associated (SERA) cells, which may play a role in the regeneration of human skin in response to injury and mesenchymal adult stem cells (MSCs), which are under investigation (by many independent researchers) for their ability to differentiate into the three main types of cells: osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat cells). Finding these specialized cells within the skin cell cultures is important because rather than undergoing a surgical organ or tissue transplantation to replace diseased or destroyed tissue, patients may one day be able to benefit from procedures by which stem cells are extracted from their skin, reprogrammed to differentiate into specific cell types and reimplanted into their bodies to exert a therapeutic effect. Research in this area is ongoing.

Finding these rare adult stem cell-like subpopulations in human skin is an exciting discovery and provides the first step towards purifying and expanding these cells to clinically relevant numbers for application to a variety of potential personalized cellular therapies for osteoarthritis, bone loss, injury and/or damage to human skin as well as many other diseases, said James A. Byrne, Ph.D., the studys lead author and Assistant Professor of Molecular and Medical Pharmacology at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. In addition to pursuing our own research investigations with Fibrocell Science using this method, we envision a time not too far in the future when we will be able to isolate and produce mesenchymal stem cells and SERA cells on demand from skin samples, which may allow other researchers in need of specialized cells to pursue their own lines of medical and scientific research.

We congratulate the UCLA researchers on the publication of their breakthrough data, which may ultimately lead to new patient-specific, personalized cellular therapies to treat various diseases, said David Pernock, Chairman and CEO of Fibrocell Science, Inc. Fibrocell Science is proud of our role in helping to establish the potential of dermal skin cells for the future of personalized, regenerative medicine. We look forward to continuing our relationship with UCLA and Dr. Byrnes team to advance this research.

Discovering Viable, Regenerative Cells in the Skin

Dr. Byrne and colleagues confirmed previous research identifying a rare population of cells in adult human skin that has a marker called the stage-specific embryonic antigen 3 (SSEA3). Dr. Byrne observed that there was a significant increase in the number of SSEA3 expressing cells following injury to human skin, supporting the hypothesis that the SSEA3 biomarker can be used to facilitate the identification and isolation of these cells with tissue-regenerative properties.

Using Fibrocells proprietary technology, the researchers collected cells from small skin samples, cultured the cells in the lab, and purified them via a technique known as fluorescence-activated cell sorting (FACS). Under FACS, cells in suspension were tagged with fluorescent markers specific for undifferentiated stem cells. This method allowed the researchers to separate the rare cell subpopulations from other types of cells.

Dr. Byrne and colleagues also observed a rare subpopulation of functional MSCs in human skin that existed in addition to the SERA cells.

Being able to identify two sub-populations of rare, viable and functional cells that behave like stem cells from within the skin is an important finding because both cell types have the potential to be investigated for diverse clinical applications, said Dr. Byrne.

Continued here:
Fibrocell Science Technology Leads to Discovery of Two Rare Adult Stem Cell-Like Subpopulations in Human Skin

Cryo-Cell International Taps Leader in Stem Cell Therapy to Serve as Chief Scientific Officer

OLDSMAR, Fla., May 3, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Cryo-Cell International, Inc. announced the appointment of Linda Kelley, Ph.D., as chief scientific officer. Dr. Kelley is responsible for overseeing Cryo-Cells state-of-the art laboratory, translational medicine initiatives and quality assurance program at its stem cell and cord blood banking facility in Oldsmar, Florida. She joins the company from the Dana Farber Cancer Institute at Harvard, where she was the director of the Connell OReilly Cell Manipulation Core Facility.

Dr. Kelley is an internationally recognized, cord blood stem cell scientist whose accomplishments have helped expand the scope of stem cell therapies from bone marrow transplantation to the treatment of heart, kidney, brain and other degenerative diseases. She was a member of the board of trustees of the Foundation for Accreditation of Cellular Therapy and chaired its Standards Committee. Dr. Kelley was one of 12 scientists selected by the Institute of Medicine of the National Academies of Science to serve on the panel that advised Congress on how to allocate $80 million in funding to optimally structure a national cord blood stem cell program.

While director of the Cell Therapy Facility at the University of Utah, she established that states first umbilical cord blood collection program that enabled families to donate their childrens cord blood to the national inventory. Dr. Kelley earned graduate and post-doctoral degrees in hematology and immunology at Vanderbilt University in Nashville, Tenn., where she also served as assistant professor in the Department of Medicine.

As a leader in our field, Cryo-Cell is delighted to have someone of Dr. Kelleys caliber directing our laboratory and translational medicine initiatives. Her expertise will ensure that we continue to exceed the industrys quality standards and maintain our tradition of offering clients the absolute best in cord blood, cord tissue, and menstrual stem cell cryopreservation services, said David Portnoy, chairman and co-CEO at Cryo-Cell. Under her guidance, Cryo-Cell will be propelled to the forefront of regenerative medicine.

Kelley replaces Julie Allickson, Ph.D., who is joining the Wake Forest Institute for Regenerative Medicine (WFIRM), where she will manage translational research. WFIRM is led by Anthony Atala, M.D., a Cryo-Cell board member and preeminent stem cell scientist.

The opportunity to work in a cutting-edge facility with a staff that is exceptionally well trained was very attractive to me, said Dr. Kelley. But equally important in my decision to join Cryo-Cell, was the commitment that co-CEOs David and Mark Portnoy have made to support the advancement of regenerative medicine through partnerships with Stanford University and private research facilities. Cryo-Cell is unique among stem cell cryopreservation firms in that regard.

About Cryo-Cell International, Inc. Cryo-Cell International, Inc. was founded in 1989. In 1992, it became the first private cord blood bank in the world to separate and store stem cells. Today, Cryo-Cell has over 240,000 clients worldwide from 87 countries. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is compliant with Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP). It is ISO 9001:2008 certified and accredited by the American Association of Blood Banks. Cryo-Cell is a publicly traded company, OTC:QB Markets Group Symbol: CCEL. Expectant parents or healthcare professionals who wish to learn more about cord blood banking and cord blood banking prices may call 1-800-STOR-CELL (1-800-786-7235) or visit http://www.cryo-cell.com/.

Forward-Looking Statement Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company's global expansion initiatives and product diversification, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the Company's ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company's menstrual stem cell technology license agreements and umbilical cord blood license agreements and their ability to provide the Company with royalty fees, the ability of the reproductive tissue storage to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy(at)cryo-cell(dot)com

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2012/5/prweb9469228.htm

Read the original post:
Cryo-Cell International Taps Leader in Stem Cell Therapy to Serve as Chief Scientific Officer

Second U-M Stem Cell Line Now Publicly Available to Help Researchers Find Treatments for Nerve Condition

Newswise ANN ARBOR, Mich. The University of Michigans second human embryonic stem cell line has just been placed on the U.S. National Institutes of Healths registry, making the cells available for federally-funded research. It is the second of the stem cell lines derived at U-M to be placed on the registry.

The line, known as UM11-1PGD, was derived from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period at the end of this sentence. That embryo was created for reproductive purposes, tested and found to be affected with a genetic disorder, deemed not suitable for implantation, and would therefore have otherwise been discarded when it was donated in 2011.

It carries the gene defect responsible for Charcot-Marie-Tooth disease, a hereditary neurological disorder characterized by a slowly progressive degeneration of the muscles in the foot, lower leg and hand. CMT, as it is known, is one of the most common inherited neurological disorders, affecting one in 2,500 people in the United States. People with CMT usually begin to experience symptoms in adolescence or early adulthood.

The embryo used to create the cell line was never frozen, but rather was transported from another IVF laboratory in the state of Michigan to the U-M in a special container. This may mean that these stem cells will have unique characteristics and utilities in understanding CMT disease progression or screening therapies in comparison to other human embryonic stem cells.

We are proud to provide this cell line to the scientific community, in hopes that it may aid the search for new treatments and even a cure for CMT, says Gary Smith, Ph.D., who derived the line and also is co-director of the U-M Consortium for Stem Cell Therapies, part of the A. Alfred Taubman Medical Research Institute. Once again, the acceptance of these cells to the registry demonstrates our attention to details of proper oversight, consenting, and following of NIH guidelines.

U-M is one of only four institutions including two other universities and one private company to have disease-specific stem cell lines listed in the national registry. U-M has several other disease-specific hESC lines submitted to NIH and awaiting approval, says Smith, who is a professor in the Department of Obstetrics and Gynecology at the University of Michigan Medical School. The first line, a genetically normal one, was accepted to the registry in February.

Stem cell lines that carry genetic traits linked to specific diseases are a model system to investigate what causes these diseases and come up with treatments, says Sue OShea, Ph.D., professor of Cell and Developmental Biology at the U-M Medical School, and co-director of the Consortium for Stem Cell Therapies.

Each line is the culmination of years of preparation and cooperation between U-M and Genesis Genetics, a Michigan-based genetic diagnostic company. This work was made possible by Michigan voters' November 2008 approval of a state constitutional amendment permitting scientists to derive embryonic stem cell lines using surplus embryos from fertility clinics or embryos with genetic abnormalities and not suitable for implantation.

The amendment also made possible an unusual collaboration that has blossomed between the University of Michigan and molecular research scientists at Genesis Genetics, a company that has grown in only eight years to become the leading global provider of pre-implantation genetic diagnosis (PGD) testing. PGD is a testing method used to identify days-old embryos carrying the genetic mutations responsible for serious inherited diseases. During a PGD test, a single cell is removed from an eight-celled embryo. The other seven cells continue to multiply and on the fifth day form a cluster of roughly 100 cells known as a blastocyst.

Genesis Genetics performs nearly 7,500 PGD tests annually. Under the arrangement between the company and U-M, patients with embryos that test positive for a genetic disease now have the option of donating those embryos to U-M if they have decided not to use them for reproductive purposes and the embryos would otherwise be discarded.

Read more from the original source:
Second U-M Stem Cell Line Now Publicly Available to Help Researchers Find Treatments for Nerve Condition

Second UM Stem Cell Line Now Available To Help Cure Nerve Condition

ANN ARBOR The University of Michigans second human embryonic stem cell line has just been placed on the U.S. National Institutes of Healths registry, making the cells available for federally funded research. It is the second of the stem cell lines derived at UM to be placed on the registry.

The line, known as UM11-1PGD, was derived from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period at the end of this sentence. That embryo was created for reproductive purposes, tested and found to be affected with a genetic disorder, deemed not suitable for implantation, and would therefore have otherwise been discarded when it was donated in 2011.

It carries the gene defect responsible for Charcot-Marie-Tooth disease, a hereditary neurological disorder characterized by a slowly progressive degeneration of the muscles in the foot, lower leg and hand. CMT, as it is known, is one of the most common inherited neurological disorders, affecting one in 2,500 people in the United States. People with CMT usually begin to experience symptoms in adolescence or early adulthood.

The embryo used to create the cell line was never frozen, but rather was transported from another IVF laboratory in the state of Michigan to the UM in a special container. This may mean that these stem cells will have unique characteristics and utilities in understanding CMT disease progression or screening therapies in comparison to other human embryonic stem cells.

We are proud to provide this cell line to the scientific community, in hopes that it may aid the search for new treatments and even a cure for CMT, says Gary Smith, Ph.D., who derived the line and also is co-director of the UM Consortium for Stem Cell Therapies, part of the A. Alfred Taubman Medical Research Institute. Once again, the acceptance of these cells to the registry demonstrates our attention to details of proper oversight, consenting, and following of NIH guidelines.

UM is one of only four institutions including two other universities and one private company to have disease-specific stem cell lines listed in the national registry. UM has several other disease-specific hESClines submitted to NIH and awaiting approval, says Smith, who is a professor in the Department of Obstetrics and Gynecology at the University of Michigan Medical School. The first line, a genetically normal one, was accepted to the registry in February.

Stem cell lines that carry genetic traits linked to specific diseases are a model system to investigate what causes these diseases and come up with treatments, says Sue OShea, professor of cell and developmental biology at the UM Medical School, and co-director of the Consortium for Stem Cell Therapies.

Each line is the culmination of years of preparation and cooperation between UM and Genesis Genetics, a Michigan-based genetic diagnostic company. This work was made possible by Michigan voters November 2008 approval of a state constitutional amendment permitting scientists to derive embryonic stem cell lines using surplus embryos from fertility clinics or embryos with genetic abnormalities and not suitable for implantation.

The amendment also made possible an unusual collaboration that has blossomed between the University of Michigan and molecular research scientists at Genesis Genetics, a company that has grown in only eight years to become the leading global provider of pre-implantation genetic diagnosis (PGD) testing. PGDis a testing method used to identify days-old embryos carrying the genetic mutations responsible for serious inherited diseases. During a PGD test, a single cell is removed from an eight-celled embryo. The other seven cells continue to multiply and on the fifth day form a cluster of roughly 100 cells known as a blastocyst.

Genesis Genetics performs nearly 7,500 PGD tests annually. Under the arrangement between the company and UM, patients with embryos that test positive for a genetic disease now have the option of donating those embryos to UM if they have decided not to use them for reproductive purposes and the embryos would otherwise be discarded.

View post:
Second UM Stem Cell Line Now Available To Help Cure Nerve Condition

Stem cell researchers map new knowledge about insulin production

Public release date: 26-Apr-2012 [ | E-mail | Share ]

Contact: Professor Palle Serup palle.serup@sund.ku.dk 01-145-402-20026 University of Copenhagen

Scientists from The Danish Stem Cell Center (DanStem) at the University of Copenhagen and Hagedorn Research Institute have gained new insight into the signaling paths that control the body's insulin production. This is important knowledge with respect to their final goal: the conversion of stem cells into insulin-producing beta cells that can be implanted into patients who need them. The research results have just been published in the well-respected journal PNAS.

Insulin is a hormone produced by beta cells in the pancreas. If these beta cells are defective, the body develops diabetes. Insulin is vital to life and therefore today the people who cannot produce their own in sufficient quantities, or at all, receive carefully measured doses often via several daily injections. Scientists hope that in the not-so-distant future it will be possible to treat diabetes more effectively and prevent secondary diseases such as cardiac disease, blindness and nerve and kidney complications by offering diabetes patients implants of new, well-functioning, stem-cell-based beta cells.

"In order to get stem cells to develop into insulin-producing beta cells, it is necessary to know what signaling mechanisms normally control the creation of beta cells during fetal development. This is what our new research results can contribute," explains Professor Palle Serup from DanStem.

"When we know the signaling paths, we can copy them in test tubes and thus in time convert stem cells to beta cells," says Professor Serup.

The new research results were obtained in a cooperative effort between DanStem, the Danish Hagedorn Research Institute and international partners in Japan, Germany, Korea and the USA. The scientific paper has just been published in the well-respected international journal PNAS (Proceedings of the National Academy of Sciences of the United States of America) entitled Mind bomb 1 is required for pancreatic -cell formation.

Better control of stem cells

The signaling mechanism that controls the first steps of the development from stem cells to beta cells has long been known.

"Our research contributes knowledge about the next step in development and the signaling involved in the communication between cells an area that has not been extensively described. This new knowledge about the ability of the so-called Notch signaling first to inhibit and then to stimulate the creation of hormone-producing cells is crucially important to being able to control stem cells better when working with them in test tubes," explains Professor Palle Serup .

Excerpt from:
Stem cell researchers map new knowledge about insulin production

How stem cell therapy can keep the immune system under control

Public release date: 26-Apr-2012 [ | E-mail | Share ]

Contact: Beth Dunham bethdunh@usc.edu 213-740-4279 University of Southern California

A new study, appearing in Cell Stem Cell and led by researchers at the University of Southern California, outlines the specifics of how autoimmune disorders can be controlled by infusions of mesenchymal stem cells.

Mesenchymal stem cells (MSC) are highly versatile stem cells that originate from the mesoderm, or middle layer of tissue, in a developing embryo. MSC can be isolated from many different kinds of human tissue, including bone marrow and the umbilical cord.

Principal investigator Songtao Shi, professor at the Ostrow School of Dentistry of USC Center for Craniofacial Molecular Biology, said that recent studies have shown the benefits of administering MSC to patients with immune-related disorders such as graft versus host disease, systemic lupus erythematosus, rheumatoid arthritis, and more.

These studies showed that infusions of MSC appeared to quell the production and function of overactive immune cells, including T- and B-lymphocytes. However, the specific mechanism behind how MSC get the immune cells under control hasn't been fully understood.

"Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell Apoptosis" shines light on how infused MSCs target and defeat overactive immune cells. Examining the effects of MSC infusion in mice with systemic sclerosis (SS)-like immune disorders, Shi and his colleagues discovered that a specific cellular mechanism known as the FAS/FAS-ligand pathway was the key to the remarkable immune system benefits.

Specifically, in mice with SS-like disorders, infusions of MSC caused T-lymphocyte death with FASL/FAS signaling and lessened symptoms of the immune disorder. However, MSC deficient in FAS-ligand failed to treat immune disorders in SS-afflicted mice.

With the hopeful results of the animal model study in mind, Shi's colleagues in China performed a pilot study with patients suffering from systemic sclerosis. Infusions of MSCs provided similar clinical benefits to patients, and experimental analysis revealed that the FASL/FAS pathway was also at work in humans with SS.

The identification of the cellular workings responsible for the stem cell treatments' success may eventually help doctors find optimal cell-based treatment for some immune diseases, Shi said.

See the original post here:
How stem cell therapy can keep the immune system under control

Your child’s milk tooth can save her life

Is your child about to lose her milk tooth? Instead of throwing it away, you can now opt to use it to harvest stem cells in a dental stem cell bank for future use in the face of serious ailments. Now thats a tooth fairy story coming to life.

Still relatively new in India, dental stem cell banking is fast gaining popularity as a more viable option over umbilical cord blood banking.

Stem cell therapy involves a kind of intervention strategy in which healthy, new cells are introduced into a damaged tissue to treat a disease or an injury.

The umbilical cord is a good source for blood-related cells, or hemaotopoietic cells, which can be used for blood-related diseases, like leukaemia (blood cancer). Having said that, blood-related disorders constitute only four percent of all diseases, Shailesh Gadre, founder and managing director of the company Stemade Biotech, said.

For the rest of the 96 percent tissue-related diseases, the tooth is a good source of mesenchymal (tissue-related) stem cells. These cells have potential application in all other tissues of the body, for instance, the brain, in case of diseases like Alzheimers and Parkinsons; the eye (corneal reconstruction), liver (cirrhosis), pancreas (diabetes), bone (fractures, reconstruction), skin and the like, he said.

Mesenchymal cells can also be used to regenerate cardiac cells.

Dental stem cell banking also has an advantage when it comes to the process of obtaining stem cells.

Obtaining stem cells from the tooth is a non-invasive procedure that requires no surgery, with little or no pain. A child, in the age group of 5-12, is any way going to lose his milk tooth. So when its a little shaky, it can be collected with hardly any discomfort, Savita Menon, a pedodontist, said.

Moreover, in a number of cases, when an adolescent needs braces, the doctor recommends that his pre-molars be removed. These can also be used as a source for stem cells. And over and above that, an adults wisdom tooth can also be used for the same purpose, Gadre added.

Therefore, unlike umbilical cord blood banking which gives one just one chance - during birth - the window of opportunity in dental stem cell banking is much bigger.

Visit link:
Your child’s milk tooth can save her life

Stem cell that may aid healing and repair found in brain

Washington, April 24 : Scientists have discovered a new stem cell in the adult brain and they hope to put the discovery to use to develop methods that can repair diseases and injury to the brain.

These cells can proliferate and form several different cell types - most importantly, they can form new brain cells.

Analysing brain tissue from biopsies, the researchers at the Lund University for the first time found stem cells located around small blood vessels in the brain.

The cell's specific function is still unclear, but its plastic properties suggest great potential. A similar cell type has been identified in several other organs where it can promote regeneration of muscle, bone, cartilage and adipose tissue.

In other organs, researchers have shown clear evidence that these types of cells contribute to repair and wound healing.

Scientists suggested that the curative properties might also apply to the brain. The next step is to try to control and enhance stem cell self-healing properties with the aim of carrying out therapies targeted to a specific area of the brain.

"Our findings show that the cell capacity is much larger than we originally thought, and that these cells are very versatile," said Gesine Paul-Visse, Ph.D., Associate Professor of Neuroscience at Lund University.

"Most interesting is their ability to form neuronal cells, but they can also be developed for other cell types. The results contribute to better understanding of how brain cell plasticity works and opens up new opportunities to exploit these very features," Paul-Visse added.

The study is of interest to a broad spectrum of brain research. Future possible therapeutic targets range from neurodegenerative diseases to stroke.

"We hope that our findings may lead to a new and better understanding of the brain's own repair mechanisms. Ultimately the goal is to strengthen these mechanisms and develop new treatments that can repair the diseased brain," said Dr. Paul-Visse.

Go here to read the rest:
Stem cell that may aid healing and repair found in brain

Bone Repair Stem Cell Breakthrough Shows Promise

Editor's Choice
Main Category: Stem Cell Research
Article Date: 15 Feb 2012 - 8:00 PST

email to a friend   printer friendly   opinions  

Current Article Ratings:

Patient / Public:

5 (3 votes)

Healthcare Prof:
According to a study published in the February issue of the STEM CELL Translational Medicine Journal , a world-first technique for generating adult stem cells (mesenchymal stem cells [MSCs]) has been developed by researchers at the University of Queensland. This new method can be used to repair bone and possibly other organs, and will considerably affect individuals suffering from a variety of serious diseases.

Professor Nicholas Fisk, who leads the collaborative study between the UQ Clinical Research Center (UQCCR) and the UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN), explained:

"We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature.

The technique also worked on their less contentious counterparts, induced pluripotent stem cells.

To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they could form tumors.

Because only small numbers of MSCs exist in the bone marrow, and harvesting bone marrow from a healthy donor is an invasive procedure, the ability to make our own MSCs in large number in the laboratory is an exciting step in the future widespread clinical use of MSCs.

We were able to show these new forms of stem cells exhibited all the characteristics of bone marrow stem cells and we are currently examining their bone repair capability."

Ernst Wolvetang, co-researcher on the study and AIBN Associate Professor, explained that the technique had overcome a considerable obstacle in the translation of stem cell-based therapy.

Wolvetang said: "We are very excited by this research, which has brought together stem cell researchers from two of the major UQ research hubs UQCCR and AIBN."

Written by: Grace Rattue

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our stem cell research section for the latest news on this subject. UniQuest, The University of Queensland's main commercialization company, invites parties interested in licensing the intellectual property relating to this discovery to contact UniQuest on 3365 4037 or lifesciences@uniquest.com.au.

Source: University of Queensland

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Grace Rattue. "Bone Repair Stem Cell Breakthrough Shows Promise." Medical News Today. MediLexicon, Intl., 15 Feb. 2012. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/articles/241706.php&gt;

APA

Please note: If no author information is provided, the source is cited instead.


Rate this article:
(Hover over the stars then click to rate) Patient / Public:
or Health Professional:

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


View original post here:
Bone Repair Stem Cell Breakthrough Shows Promise

Stem cell institute to work with foreign agencies

California's $3 billion stem cell agency, now more than 7 years old, has joined research partnerships with science and health agencies in eight foreign countries, the San Francisco institute announced.

The agreements call for collaboration in efforts aimed at speeding stem cell research from the laboratory to the hospital, where researchers hope that basic human cells will be programmed to treat scores of human degenerative diseases.

Research partnerships between American and foreign stem cell scientists are encouraged, but the California institute's funds would only be spent within the state, institute officials said.

Alan Trounson, president of the California Institute for Regenerative Medicine, signed agreements with stem cell funding agencies in Brazil and Argentina last week, he said Thursday.

"Both Brazil and Argentina have strong and robust stem cell research communities in basic science and transitional clinical science, which should create exciting synergies with many scientists in California," Trounson said in a statement.

He has signed similar pacts with stem cell agencies in Canada, Britain, France, Spain, Australia, Japan, China and Indiana.

The California institute was created in 2004 after Proposition 71, a $3 billion bond issue, was approved by California voters at a time when use of federal funds was barred for research into the promising field of embryonic stem cells.

So far the state agency has committed $1.2 billion to scientists and training centers at 56 California institutions, and the rest of the bond money should last until 2020, a spokesman said.

This article appeared on page C - 9 of the SanFranciscoChronicle

See the article here:
Stem cell institute to work with foreign agencies

Cryo-Save Group N.V.: Revenue up 4% to €41.9 million

Cryo-Save Group N.V. (Euronext: CRYO, `Cryo-Save`, or `the Group`), the leading international stem cell storage brand and the largest family stem cell bank in Europe, has published its financial results for the year ended 31 December 2011.

Financial highlights

Revenue up 4% to 41.9 million (2010: 40.4 million) Operating expenses before depreciation and amortisation increased with 1.6 million mainly due to further investments in Cryo-Lip (0.8 million) and acquisition impact (0.7 million) EBITDA*: 6.3 million (2010: 7.3 million) EBITA**: 4.5 million (2010: 5.8 million) Operating profit: 2.9 million (2010: 4.5 million) Profit before taxation: 3.0 million (2010: 3.9 million) Net profit: 2.3 million (2010: 2.6 million) Basic earnings per share 25.0 euro cents (2010: 27.6 euro cents) Robust net cash from operating activities 6.2 million (2010: 2.8 million) Solid cash position of 7.0 million as at 31 December 2011 (2010: 6.0 million) Dividend per share of 0.08, up 14% (2010: 0.07)

* EBITDA is defined as Earnings Before Interest, Taxation Depreciation and Amortisation ** EBITA is defined as Earnings Before Interest, Taxation and Amortisation of identified intangible assets

Operational highlights

39,900 new samples stored in 2011, up 4% compared to previous year (2010: 38,300). Of these, 25,200 were new cord blood samples and 14,700 new cord tissue samples 204,000 samples have been stored in total at 31 December 2011 67% of new customers opt for combined service of cord blood and cord tissue storage Acquisition of Serbian distributor Life R.F. for 2.3 million in cash and 30,000 Cryo-Save shares Cryo-Save USA founded, to commercialize and develop the Cryo-Lip service in North America Cryo-Save South Africa joint venture established and stem cell processing and storage laboratory opened in Cape Town together with John Daniel Holdings and Lazaron Biotechnologies A six-year-old girl from Portugal with Cerebral Palsy was treated at Duke University in the US with her own cord blood stem cells, which were stored and released by Cryo-Save

Outlook

Revenue increased with 1.4 million to 41.9 million, largely due to increased sales volumes in several countries, acquisitions and increased number of new cord tissue samples, partly offset by lower business volume in mainly Southern Europe. The impact of the economic crisis also resulted in a significantly lower number of births in almost all countries. An increasing demand for discounts on the service fee and instalment plans to facilitate the payment of the service fee has been another factor affecting revenue growth.

The gross profit margin decreased with 1% to 66.6%, among others due to an increased demand for higher reimbursements of the collection of the umbilical cord blood and cord tissue in the hospitals. The gross profit margin remained at the same level compared to the second half of 2010 (66.5%).

Operational expenses increased with 1.6 million due to incremental expenses related to Cryo-Lip (0.8 million), and the impact of the acquisitions of Tissue Bank Cryo Center Bulgaria AD ("TBCCB") and Life R.F. doo, Serbia ("Life") (0.7 million).

Read the rest here:
Cryo-Save Group N.V.: Revenue up 4% to €41.9 million

Cryo-Save Group N.V.: Revenue up 4% to EUR41.9 million

Cryo-Save Group N.V. (Euronext: CRYO, Cryo-Save, or the Group), the leading international stem cell storage brand and the largest family stem cell bank in Europe, has published its financial results for the year ended 31 December 2011.

Financial highlights

Revenue up 4% to EUR41.9 million (2010: EUR40.4 million) Operating expenses before depreciation and amortisation increased with EUR1.6 million mainly due to further investments in Cryo-Lip() (EUR0.8 million) and acquisition impact (EUR0.7 million) EBITDA(*): EUR6.3 million (2010: EUR7.3 million) EBITA(**): EUR4.5 million (2010: EUR5.8 million) Operating profit: EUR2.9 million (2010: EUR4.5 million) Profit before taxation: EUR3.0 million (2010: EUR3.9 million) Net profit: EUR2.3 million (2010: EUR2.6 million) Basic earnings per share 25.0 euro cents (2010: 27.6 euro cents) Robust net cash from operating activities EUR6.2 million (2010: EUR 2.8 million) Solid cash position of EUR7.0 million as at 31 December 2011 (2010: EUR6.0 million) Dividend per share of EUR0.08, up 14% (2010: EUR0.07) () (*) EBITDA is defined as Earnings Before Interest, Taxation Depreciation and Amortisation (**) EBITA is defined as Earnings Before Interest, Taxation and Amortisation of identified intangible assets

Operational highlights

39,900 new samples stored in 2011, up 4% compared to previous year (2010: 38,300). Of these, 25,200 were new cord blood samples and 14,700 new cord tissue samples 204,000 samples have been stored in total at 31 December 2011 67% of new customers opt for combined service of cord blood and cord tissue storage Acquisition of Serbian distributor Life R.F. for EUR2.3 million in cash and 30,000 Cryo-Save shares Cryo-Save USA founded, to commercialize and develop the Cryo-Lip() service in North America Cryo-Save South Africa joint venture established and stem cell processing and storage laboratory opened in Cape Town together with John Daniel Holdings and Lazaron Biotechnologies A six-year-old girl from Portugal with Cerebral Palsy was treated at Duke University in the US with her own cord blood stem cells, which were stored and released by Cryo-Save

Outlook

* Cryo-Save has a strong strategic position and product portfolio to further enhance its business * Cryo-Save will continue to collaborate with new partners and make acquisitions in line with its strategy to grow in current markets as well as in new geographies * Promising developments continue in the use of stem cell technology in the treatment of diseases. Thus enhancing the added value of Cryo-Saves high- tech storage solutions of stem cells * Fast growing fields of cellular therapy and regenerative medicine offer further attractive market potential for Cryo-Save * The Group is confident it will continue to maintain its market leading position as the leading international stem cell storage brand and the largest family stem cell bank in Europe

Revenue increased with EUR1.4 million to EUR41.9 million, largely due to increased sales volumes in several countries, acquisitions and increased number of new cord tissue samples, partly offset by lower business volume in mainly Southern Europe. The impact of the economic crisis also resulted in a significantly lower number of births in almost all countries. An increasing demand for discounts on the service fee and instalment plans to facilitate the payment of the service fee has been another factor affecting revenue growth.

The gross profit margin decreased with 1% to 66.6%, among others due to an increased demand for higher reimbursements of the collection of the umbilical cord blood and cord tissue in the hospitals. The gross profit margin remained at the same level compared to the second half of 2010 (66.5%).

Operational expenses increased with EUR1.6 million due to incremental expenses related to Cryo-Lip() (EUR0.8 million), and the impact of the acquisitions of Tissue Bank Cryo Center Bulgaria AD ("TBCCB") and Life R.F. doo, Serbia ("Life") (EUR0.7 million).

See the article here:
Cryo-Save Group N.V.: Revenue up 4% to EUR41.9 million

New stem cell found in brain: Finding could be key to developing methods to heal and repair brain injury and disease

ScienceDaily (Apr. 20, 2012) esearchers at Lund University in Sweden have discovered a new stem cell in the adult brain. These cells can proliferate and form several different cell types -- most importantly, they can form new brain cells. Scientists hope to take advantage of the finding to develop methods to heal and repair disease and injury in the brain.

Analyzing brain tissue from biopsies, the researchers for the first time found stem cells located around small blood vessels in the brain. The cell's specific function is still unclear, but its plastic properties suggest great potential.

"A similar cell type has been identified in several other organs where it can promote regeneration of muscle, bone, cartilage and adipose tissue," said Patrik Brundin, M.D., Ph.D., Jay Van Andel Endowed Chair in Parkinson's Research at Van Andel Research Institute (VARI), Head of the Neuronal Survival Unit at Lund University and senior author of the study.

In other organs, researchers have shown clear evidence that these types of cells contribute to repair and wound healing. Scientists suggest that the curative properties may also apply to the brain. The next step is to try to control and enhance stem cell self-healing properties with the aim of carrying out targeted therapies to a specific area of the brain.

"Our findings show that the cell capacity is much larger than we originally thought, and that these cells are very versatile," said Gesine Paul-Visse, Ph.D., Associate Professor of Neuroscience at Lund University and the study's primary author. "Most interesting is their ability to form neuronal cells, but they can also be developed for other cell types. The results contribute to better understanding of how brain cell plasticity works and opens up new opportunities to exploit these very features."

The study, published in the journal PLoS ONE, is of interest to a broad spectrum of brain research. Future possible therapeutic targets range from neurodegenerative diseases to stroke.

"We hope that our findings may lead to a new and better understanding of the brain's own repair mechanisms," said Dr. Paul-Visse. "Ultimately the goal is to strengthen these mechanisms and develop new treatments that can repair the diseased brain."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Link:
New stem cell found in brain: Finding could be key to developing methods to heal and repair brain injury and disease

Pet stem cell biz booming for MediVet

In just two years after going commercial, MediVet Americas headquarters in Nicholasville has seen exponential growth with no sign of slowing down.

The privately owned company is one of a handful of developers and researchers worldwide working on stem-cell regenerative therapy for animals suffering from osteoarthritis, hip dysplasia and other degenerative diseases. MediVet also provides other services such as stem-cell storage and selling stem cell extraction kits to veterinarians around the globe.

Founded as a research company six years ago in Sydney, Australia, MediVet as a whole is now represented in 26 counties and has hubs in 44 American states.

In 2010, there were only two full-time working employees at the office and lab building located in Nicholasville. The headquarters now employs 12 people with more sales, research and manufacturing jobs expected to open up in the next few months.

The Nicholasville lab has seen an increase of 3,000 percent in monetary growth since February 2011, said director of lab services Katherine Wilkie.

A University of Kentucky graduate, Wilkie said the lab has seen tremendous increase in clientele, as well. Currently, the facility banks approximately 600 different animal stem cells that account for more than 2,000 samples from all across the country and Canada.

In September, we received a sample from Alaska, she said. That now gives us an animal from each of the 50 states.

Stem-cell regenerative therapy has been used to treat everything from a mouse to an elephant, and Wilkie said they may soon do the procedure on a dolphin.

The companys blooming success boils down to its devolvement of advanced technologies in extracting, activating and storing stem cells that have cut the cost by one-third of their competitors, CEO Jeremy Delk said.

MediVets research and developments has made the procedures and other services they offer economically viable to the average pet owner, he said.

Go here to see the original:
Pet stem cell biz booming for MediVet

California's stem cell agency ponders its future

LOS ANGELES (AP) -- The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions.

The taxpayer-funded institute wielded the extraordinary power to dole out $3 billion in bond proceeds to fund embryonic stem cell work with an eye toward treatments for a host of crippling diseases. Midway through its mission, with several high-tech labs constructed, but little to show on the medicine front beyond basic research, the California Institute for Regenerative Medicine faces an uncertain future.

Is it still relevant nearly eight years later? And will it still exist when the money dries up?

The answers could depend once again on voters and whether they're willing to extend the life of the agency.

Several camps that support stem cell research think taxpayers should not pay another cent given the state's budget woes.

"It would be so wrong to ask Californians to pony up more money," said Marcy Darnovsky of the Center for Genetics and Society, a pro-stem cell research group that opposed Proposition 71, the state ballot initiative that formed CIRM.

Last December, CIRM's former chairman, Robert Klein, who used his fortune and political connections to create Prop 71, floated the possibility of another referendum.

CIRM leaders have shelved the idea of going back to voters for now, but may consider it down the road. The institute recently submitted a transition plan to Gov. Jerry Brown and the Legislature that assumes it will no longer be taxpayer-supported after the bond money runs out. CIRM is exploring creating a nonprofit version of itself and tapping other players to carry on its work.

"The goal is to keep the momentum going," board Chairman Jonathan Thomas said in an interview.

So far, CIRM has spent some $1.3 billion on infrastructure and research. At the current pace, it will earmark the last grants in 2016 or 2017. Since most are multi-year awards, it is expected to stay in business until 2021.

Originally posted here:
California's stem cell agency ponders its future

Scientists urged to share data on stem cells research

By Noimot Olayiwola
Staff Reporter
Researchers and scientists in the field of both embryonic and adult stem cells research in the Middle East were yesterday urged to be more open to collaboration and networking among themselves in order to build on their already acquired and existing strengths for the betterment of the future use of stem cells in curing genetic diseases in the region.
Stem cells are ‘unspecialised’ cells that are able to divide and produce copies of themselves and having the potential to differentiate, that is, to produce other cell types in the body.
Speaking on how to further expand the scope of stem cell research in the region during a panel discussion yesterday at the ongoing Qatar International Conference on Stem Cell Science and Policy, Weill Cornell Medical College in Qatar’s Dr Jeremie Arash Rafii Tabrizi said there was the need for the region’s researchers in the field of stem cells to know each other and come together to network and form collaborations.
“I believe that each and everyone in the field within this region has built some sort of strength while conducting their individual researches, so I will suggest that we all come together to put heads together and also explore how we can benefit from our colleagues elsewhere. And if we can be more diseases-focused in our researches, I believe it is a good way to move forward,” he noted.
Making a presentation on “Stem Cell Research: From Promise to Practice”, Dr Aida al-Aqeel, of Riyadh Military Hospital’s paediatrics department, maintained that it would take a while before stem cell research can become a ‘clinical reality’.
“Despite that stem cell research is at the forefront of the need for research to cure most degenerative diseases, it will still take a long way for the stem cell research to become achievable clinically because the embryonic stem cells (ESCs) have huge therapeutic potential as they can give rise to every cell type in the body (pluripotency) as compared to adult stem cells (ASCs) from certain adult tissues that can only differentiate into a limited range of cell types,” she said.
“However, this research raises sensitive ethical and religious arguments, which are balanced against possible great benefit of such research for the patients suffering from so far incurable diseases. Serious questions remain about safety,” she said, noting that the ability for stem cells to be expanded in culture without genetic and epigenetic abnormalities and their ability to form functional cell types in vitro and in vivo, and their immuno-compatibility with the patient still need to be studied.
“In Saudi Arabia, for the last five years, the Stem Cell Therapy Programme has been established at King Faisal Specialist Hospital and Research Centre with the launch of 10 projects. Embryonic stem cell therapy for genetics metabolic disorders is one of the most promising modalities for the therapy and prevention of mentally and physically handicapped in children,” she said while sharing experiences from the KSA.
She pointed out how Islamic teachings make embryonic stem cell research and therapeutic technique, and its modality of treatment permissible as well as the Islamic perspectives about reproductive/therapeutic cloning.
“The focus of research community should be on developing human research capacity in both ASCs and ESCs. Each type of research will take time to mature. The ethical debate will need to produce acceptable policy and regulatory compromises so that the regulatory burden can be reduced and investors’ risk aversion can be overcome,” she stated.
Other speaker during the session moderated by WCMC-Q dean Dr Javaid Sheikh were Professor Hossein Baharvand from the Royan Institute for Reproductive Biomedicine Stem Cell Biology and Technology on “A Chemical Approach to Efficient Generating Embryonic and Germline-derived Pluripotent Stem Cells”.

Continue reading here:
Scientists urged to share data on stem cells research

The umbilical cord blood stem cells break new ground in healing hard-to-cure diseases – Video

28-10-2011 21:43 [Anchor] With the increasing number of the patients who suffer from the hard-to-cure diseases, various treatments have been tried for eliminating the cause. Recently, the "umbilical cord blood stem cells" are brought up to be the new solutions and give hope to the patients. Our next report has the details. [Reporter] The stem cells are basic cells for making about two hundred and sixty of body cells such as bones, bloods, and nerves. By duplicating themselves, the stem cells restore the damaged cells. Among them, especially, the umbilical cord blood stem cells are highly effective on curing the hard-to-cure diseases. Those cells, which have the functions to investigate and chase the specific cells, are from the cellular tissue of the umbilical cord. With this, it is possible to load the anti-cancer genes or healing substances so as to fight off the germs selectively. [Interview - Won-il Oh, Director of Research of MEDIPOST] ~ The umbilical cord blood stem cells go inside of the body and find the affected area with specific disease. It is used for curing the incurable diseases like stroke, brain tumor and arthritis. The "umbilical cord blood stem cell therapy products" regenerate the cells and tissues that are damaged from diseases. Since the products are made from the adult stem cells extracted from the cord blood, the differentiation with the existing medicine is expected. Along with this, the number of people who are using the "cord blood bank" has been increasing ...

The rest is here:
The umbilical cord blood stem cells break new ground in healing hard-to-cure diseases - Video

Stem cell fertility treatments could be risky for older women

Harvard scientists are challenging traditional medical logic that dictates that women are born with a finite amount of eggs.  The scientists said they have discovered the ovaries of young women harbor rare stem cells that are in fact capable of producing new eggs.

If properly harnessed, those stem cells may someday lead to new treatments for women suffering from infertility due to cancer or other diseases – or for those who are simply getting older, according to the researchers.  Lead researcher Jonathan Tilly of Harvard's Massachusetts General Hospital has co-founded a company, OvaScience Inc., to try to develop the findings into fertility treatments.

The idea that women are born with all the egg cells – called oocytes – they’ll ever have has been called into question by past research, which found egg-producing stem cells in adult mice.

In this latest study, Harvard researchers, in collaboration with Japanese scientists, used donated frozen ovaries from 20 year olds and ‘fished out’ the purported stem cells.  

The researchers inserted a gene into the stem cells, which caused them to glow green.  If the cells produced eggs, those would glow green, too.

The researchers first watched through a microscope as new eggs grew in a lab dish.  They then implanted the human tissue under the skin of mice to provide a nourishing blood supply.  Within two weeks, they observed green-tinged cells forming.

While the work of the Harvard scientists does show potential, there are still questions as to whether the cells are capable of growing into mature, usable eggs.

If so, researchers said, it might be possible one day to use the stem cells in order to grow eggs in lab dishes to help preserve cancer patients’ fertility, which can be harmed by chemotherapy.

Now, I just want to say, while this would be a remarkable discovery – if it pans out – I do have a few concerns. 

I think for specific patients in prime, childbearing ages, who are at risk of losing their fertility for one reason or another, this could be a fruitful discovery for them.

Be that as it may, I am totally against commercializing this technology to the point where women going through menopause look at this as another way of getting pregnant.  For many, this could create incredibly high-risk pregnancies, among other medical problems.

While science is capable of great discovery and innovation – particularly in the field of stem cells – I believe that with reproductive medicine, we should move forward with great caution to minimize any risk to mother and baby.

Continued here:
Stem cell fertility treatments could be risky for older women

Seminar to focus on stem cell research development

The latest discoveries and promises of stem cell research and the development of new therapeutic approaches for a variety of diseases will be in focus at the Qatar International Conference on Stem Cell Science and Policy 2012 which begins today.
The four-day event, being held at Qatar National Convention Centre, is a milestone in Qatar Foundation’s ongoing collaboration with the James A Baker III Institute for Public Policy at Rice University, Houston, Texas, US.
The aim of QF’s joint initiative with the Baker Institute’s International Programme on Stem Cell Science Policy is to develop stem cell research in Qatar as well as to find ways to address the shared challenges of community support for stem cell research in Doha and Houston.
To accomplish this goal, the programme has supported several events since its inception, including meetings, workshops, and training programmes in both cities.
The conference, which brings together eminent international as well as regional scientists, ethicists and policymakers, will also present the developed policy options that account for cultural, ethical and religious factors.
The event will draw attention to Qatar’s position in the development of stem cell research in the region and the world, given that research on stem cell as a national priority has already been initiated in the country’s best research institutions.
The conference objectives are to raise the awareness about Qatar’s initiative in promoting stem cell research, present the latest developments, and highlight the different religious views regarding stem cell research specifically the Islamic view.
The pros and cons of various options for regulating stem cell research and how scientists should address conflicting and confusing national policies and assess the different models of international collaboration will be discussed.
The conference also intends to interface with other institutions outside Qatar and contribute to the exchange of scientific knowledge to enhance the promotion of a scientific culture in the region and globally.
The keynote speakers are ambassador Edward P Djerejian (Baker Institute), Irving Weissman (Stanford University), Alan Trounson (president, California Institute for Regenerative Medicine), David Baltimore (president emeritus, Robert Andrews Millikan Professor of Biology, California Institute of Technology), Roger Pedersen (Department of Surgery, University of Cambridge) and Lawrence Corey (president and director, Fred Hutchinson Cancer Research Centre).
The conference, supported by Qatar Biomedical Research Institute, will also feature a number of invited speakers from across the world.

Read more from the original source:
Seminar to focus on stem cell research development

Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

NEW YORK & PETACH TIKVAH--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem cells, generated with Brainstorm’s NurOwn™ technology, provide hope for Huntington disease's patients.

In the preclinical studies conducted by leading scientists including Professors Melamed and Offen of Tel Aviv University and originally reported in Experimental Neurology, patients' bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) that were transplanted into an animal model of Huntington disease showed therapeutic benefits.

Addressing the role of these MSC-NTF cells in Huntington disease, Professor Daniel Offen explains, "the premise is that such cells can be transplanted safely into affected areas of the brain, and thereby serve as vehicles for delivering neurotrophic factors." Offen expressed his hope that this cell-based therapy may eventually progress to the clinic.

BrainStorm is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results have shown that Brainstorm’s NurOwn™ therapy is safe, does not show any significant treatment-related adverse events, and have also shown certain signs of beneficial clinical effects.

Follow this link for the Research Highlights page in Nature Reviews Neurology (starts Feb. 28th ): http://www.nature.com/nrneurol/journal/vaop/ncurrent/index.html

To read the Original Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. follow this link: http://www.sciencedirect.com/science/article/pii/S0014488612000295

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot (www.ramot.org) at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

More here:
Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease